Wildfire Smoke Negatively Affects Newborn Health: Study koreabizwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreabizwire.com Daily Mail and Mail on Sunday newspapers.
CHICAGO - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT and lazertinib, a. | June 5, 2023
In data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, amivantamab-vmjw plus lazertinib demonstrated promise as a first-line treatment for patients with advanced EGFR-mutated non-small cell lung cancer.
There is an urgent need for more targeted treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), although first-line treatment has shown potential in a clinical study.